General Information of Drug (ID: DMYFUOP)

Drug Name
TTP-547 Drug Info
Synonyms Glucokinase activator (diabetes), TransTech Pharma
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMYFUOP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Glucokinase (GCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY-2599506 DMMI0RH Diabetic complication 5A2Y Phase 2 [3]
AMG 151 DMGOFL3 Type-2 diabetes 5A11 Phase 2 [3]
PF-04991532 DM94NBE Diabetic complication 5A2Y Phase 2 [4]
GK1-399 DMLFSMX Diabetic complication 5A2Y Phase 2 [5]
LY-2608204 DM4EF9Y Type-2 diabetes 5A11 Phase 2 [6]
PF-04937319 DMQMF4O Type-2 diabetes 5A11 Phase 2 [7]
AZD1656 DMUE90I Diabetic complication 5A2Y Phase 2 [8]
TTP399 DMBKQSZ Type 2 diabetes 5A11 Phase 2 [9]
HMS5552 DMRYM03 Type-2 diabetes 5A11 Phase 1 [10]
BMS-820132 DMCX0H7 Type-2 diabetes 5A11 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucokinase (GCK) TTDLNGZ HXK4_HUMAN Activator [2]

References

1 New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. Rob M. Jones, David E. Thurston, David Rotella, Salvatore Guccione, Ana Martinez. Page(92).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
3 This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
4 The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
5 Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
6 Clinical pipeline report, company report or official report of Eli Lilly.
7 Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
8 Clinical pipeline report, company report or official report of AstraZeneca (2009).
9 Clinical pipeline report, company report or official report of vTv Therapeutics.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.